New WTC Utah Grants for Doing Business in the Middle East
October 14, 2021
Dubai, UAE | March 6-8, 2022
Join us in Dubai, UAE for the largest U.S. government-led trade mission and business development forum. Organized by the U.S. Commercial Service, Trade Winds will feature meetings with U.S. commercial diplomats from over 20 countries in the Middle East, North Africa and Sub-Saharan Africa, exciting conference programming and plenty of networking. Qualified U.S. businesses may customize their experience with optional business-to-business matchmaking meetings with pre-screened buyers, agents, distributors or joint-venture partners in the United Arab Emirates (March 8) as well as Algeria, Israel, Morocco and Qatar (March 2-3) and Saudi Arabia, Kuwait and Egypt (March 9-10).
As a part of our mission to help Utah businesses capitalize on their potential in international markets, WTC Utah is offering grant funds of $2,500 to the Utah life sciences & biotechnology industry to assist in financing this experience for your company.
Attendees will receive additional consulting services from WTC Utah at no cost. Additional funding under the STEP grant is available for qualifying applicants.
The registration deadline is rapidly approaching and spots for the event are extremely limited.
If you and your company are interested in attending Trade Winds 2022, please contact Dustin Daugherty, Director of Market Entry & Global Engagement at WTC Utah, via email at ddaugherty@wtcutah.com. Dustin will be happy to assist you in registering for the event and getting set up with the $2,500 WTC Utah grant as well as any additional STEP funds.
Recent News
- Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
- Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development
- NUSANO STABLE ISOTOPE PROGRAM ENRICHES GADOLINIUM-160 TO 99.2% PURITY
- CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
- Seek Labs Unveils BioSeeker™
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)